August 28, 2016 3:14 AM ET

Pharmaceuticals

Company Overview of H3 Biomedicine Inc.

Company Overview

H3 Biomedicine Inc., a biopharmaceutical company, is engaged in the discovery and development of small-molecule drugs to treat cancer. H3 Biomedicine Inc. has a strategic collaboration with Selvita S.A. The company was founded in 2010 and is based in Cambridge, Massachusetts. H3 Biomedicine Inc. operates as a subsidiary of Eisai Inc.

300 Technology Square

Fifth Floor

Cambridge, MA 02139

United States

Founded in 2010

Phone:

617-252-5000

Key Executives for H3 Biomedicine Inc.

President and Chief Executive Officer
Scientific Founder
Age: 60
Scientific Founder
Senior Vice President of Planning and Operations
Chief Medical Officer
Compensation as of Fiscal Year 2016.

H3 Biomedicine Inc. Key Developments

H3 Biomedicine Announces Appointment of Tarek Sahmoud as Chief Medical Officer

H3 Biomedicine Inc. announced the appointment of Tarek Sahmoud, MD, PhD, as Chief Medical Officer. Prior to joining H3 Biomedicine, Dr. Sahmoud most recently served as Vice President, Oncology Clinical Development and Medical Affairs for the United States business at Boehringer Ingelheim.

H3 Biomedicine Receives FDA Acceptance for Investigational New Drug Application

H3 Biomedicine Inc. announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application to begin Phase 1 clinical trials for its lead oncology drug candidate H3B-8800. The compound is an oral and selective small molecule modulator of splicing factor 3b subunit 1 (SF3B1), which is being developed by H3 Biomedicine as an anticancer therapeutic agent for the potential treatment of select hematologic malignancies. The SF3B1 program represents H3’s most advanced effort in its strategy to impact deregulated RNA homeostasis in cancer through RNA splicing modulation. The spliceosome is a complex molecular machine found in the nucleus of cells and is responsible for the removal of noncoding introns from a transcribed pre-mRNA. Recurrent heterozygous mutations in several core members (SF3B1, U2AF1, SRSF2, ZRSR2) of the spliceosome have been identified in various cancers and lead to aberrant mRNA splicing that may contribute to disease pathogenesis. H3 is building on its discoveries around targeting SF3B1 and splice modulation to design novel treatments for various cancers.

H3 Biomedicine Inc. Presents at BBC BD Boston, Mar-09-2016 01:00 PM

H3 Biomedicine Inc. Presents at BBC BD Boston, Mar-09-2016 01:00 PM. Venue: The Westin Copley Place, 10 Huntington Avenue, Boston, MA 02116, United States. Speakers: Marlus Warmuth.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact H3 Biomedicine Inc., please visit www.h3biomedicine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.